Cancer Immunology and Immunotherapy

项目总结（见说明）： 癌症免疫学和免疫治疗 癌症免疫学和免疫治疗计划的研究正在探索淋巴恶性肿瘤的基础，转化和临床方面以及癌症免疫治疗的各种方法。该计划成员的总体目标是提高我们对基于免疫系统的细胞信号传导，分化，贩运和死亡机制的理解，长期目标是提高我们治疗淋巴恶性肿瘤的能力，并诱导更有效的抗癌免疫反应。该计划还侧重于通过癌症免疫治疗的创新临床试验将实验室进展转化为临床。 该方案中有两个相互重叠的主要主题。第一个主题是癌症免疫学。这个主题的重点是淋巴细胞信号传导，宿主反应和干细胞生物学的基础研究。补充翻译癌症免疫治疗主题的重点是类风湿性肿瘤和癌症疫苗的免疫治疗。巨蟹座的主要成就 在过去的资助期间，免疫学和免疫治疗计划包括了解信号分子的作用，包括TNFR相关因子（TRAFs），淋巴恶性肿瘤，抗CD20治疗抗体的作用机制分析，TLR9激动剂作为免疫抑制剂的开发，以及前列腺癌疫苗的开发。有许多过去和 在项目成员之间以及与其他癌症中心项目成员之间开展富有成效的合作。最值得注意的是通过淋巴瘤孢子发生的协作，翻译研究.该计划由来自1个基础科学和5个临床部门和1个学院的28名成员组成。 同行评审，该计划的研究资金总额为960万美元，其中150万美元来自NCI。 项目成员在前一个资助期内发表了322篇与癌症相关的论文。在这些出版物中，16%是计划内的，15%是计划间的，4%是计划内和计划间的，总共有36%是合作出版物。

PROJECT SUMMARY (See instructions): Cancer Immunology & Immunotherapy Research in the Cancer Immunology & Immunotherapy Program is exploring basic, translational and clinical aspects of lymphoid malignancies and various approaches to cancer immunotherapy. The overall goal of the members of the program is to improve our understanding of the mechanisms of immune system-based cell signaling, differentiation, trafficking, and death with the long-term goal of enhancing our ability to treat lymphoid malignancies and induce a more effective anti-cancer immune response. The program also focuses on translating laboratory advances to the clinic through innovative clinical trials in cancer immunotherapy. There are two major overlapping themes within the Program. The first Theme is Cancer Immunology. The emphasis within this Theme is basic research in Lymphocyte Signaling, Host Responses, and Stem Cell Biology. The emphasis of the complementary translational Cancer Immunotherapy Theme is upon Immunotherapy of Lymphoid Malignancies and Cancer Vaccines. Major accomplishments of the Cancer Immunology and Immunotherapy Program over the past funding period include understanding the roles of signaling molecules, including TNFR-associated factors (TRAFs), in lymphoid malignancies, analysis of the mechanisms of action of ahti-CD20 therapeutic antibodies, development of TLR9 agonists as immunotherapeutic agents, and development of a prostate cancer vaccine. There are numerous past and present productive collaborations both between members of the Program, and with members of other Cancer Center programs. Most notable are the collaborative, translational studies taking place through the Lymphoma SPORE. The program consists of 28 members from 1 basic science and 5 clinical departments and 1 College. Peer-reviewed, research funding forthis program totals $9.6 million with $1.5 million coming from the NCI. Program members published 322 cancer-related papers over the prior funding period. Ofthese publications, 16% were intraprogrammatic, 15% were interprogrammatic and 4% were both intra and interprogrammatic, for a total of 36% collaborative publications.